Developer docs
API playgroundTry for free, no card

Search company profiles

Human Regenerative Technologies

Full company profile

uuid000nfad

Namestring
Human Regenerative Technologies
Legal namestring
Human Regenerative Technologies, LLC
Websiteurl
humantissue.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Human Regenerative Technologies, LLC (HRT®) is a U.S.-based biologics company founded in 2013 and headquartered in El Segundo, California. The company specializes in processing and distributing human amniotic and placental tissue allografts under Section 361 of the Public Health Service Act and 21 CFR Part 1271. Since December 31, 2018 it has operated as a majority-owned subsidiary of Skye Biologics Holdings, LLC, serving as the primary allograft tissue processor for Skye Orthobiologics' placental and amniotic tissue product offering. HRT reports over 250,000 cumulative implants and a management team with more than 50 years of combined experience in the 361 tissue allograft space.

HRT's core technology is the proprietary HydraTek® Process, which the company positions as a differentiated tissue processing method that preserves placental tissue in its natural hydrated state and improves handling and delivery characteristics for clinical use. The product portfolio is organized around wound care applications and extends into surgical soft tissue repair and orthopedic use cases, targeting hospitals, ambulatory surgical centers, and wound care clinics. The company is accredited by the American Association of Tissue Banks (AATB), registered with the FDA, and holds tissue bank licenses in California, New York, Maryland, Oregon, Delaware, and Illinois, with additional licensure in Canada.

HRT's business model is a direct B2B field-sales motion selling per-product and per-procedure allograft units to healthcare institutions, with marketing concentrated at orthopedic, foot and ankle, and wound care conferences (AAOS, ACFAS, SAWC). No headcount, revenue, valuation, or funding data are publicly disclosed; pricing is not published and is negotiated through institutional procurement channels.

Short descriptiontext

Human Regenerative Technologies, LLC is a U.S. biologics company that processes and distributes human amniotic and placental tissue allografts via its proprietary HydraTek® Process, selling directly to hospitals, surgical centers, and wound care clinics across seven U.S. states and Canada.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEl Segundo, United States
HQ citystring
El Segundo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
amniotic tissue allografts, placental tissue processing, wound care allografts, orthobiologic tissue products, regenerative tissue banking
Industry3 codes
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Tissue Allografts
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Amniotic & Placental Allograft Products
TypeOne Time License
Description

HRT generates revenue through the sale of human amniotic and placental tissue allografts, including wound care and soft tissue products derived from placental connective tissues. Revenue is generated on a per-implant/product transaction basis rather than a recurring subscription model.

humanregenerativetechnologies.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1HydraTek®
Description

Revolutionary technology and processing method for harvesting and preserving placenta tissue in its natural hydrated state for use as transplant allografts.

humanregenerativetechnologies.com
Core offering1 text field

Human Regenerative Technologies processes and distributes human amniotic and placental tissue allografts for medical applications, primarily wound care and soft tissue repair. Products are manufactured using the proprietary HydraTek® Process, which preserves placental and amniotic tissue in its natural hydrated state to maintain tissue integrity and function. All allografts are regulated under Section 361 of the PHS Act and 21 CFR Part 1271.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Over 250,000 implants performed to date
Product overview1 text field

Human Regenerative Technologies (HRT®) offers a unified portfolio of human amniotic and placental tissue allografts for medical applications. The core offering centers on the proprietary HydraTek® Process technology, which processes and preserves placental tissues in their natural hydrated state. Products include wound care applications derived from amniotic and placental tissues. All products are regulated under 361 of the PHS Act and 21 CFR Part 1271 as human cell, tissue, and cellular and tissue-based products (HCT/Ps).

Product and service1 record
1Wound Care Allografts
CategoryWound Care Allografts
Description

Human amniotic and placental tissue allografts designed for wound care applications, processed using the proprietary HydraTek® technology to preserve tissue in its natural hydrated state. Sold to hospitals, surgical centers, and wound care clinics for patient wound care management.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AlloSource is a non-profit tissue bank that processes and distributes allografts including amniotic and placental products, directly comparable as a tissue processor serving wound care and orthopedic surgeons.

TypeDirect peer
Description

MiMedx develops and markets amniotic membrane tissue allografts (EpiFix, AmnioFix) for wound care and surgical applications, directly overlapping with HRT's placental/amniotic allograft portfolio and customer base.

TypeBroad incumbent
Description

Smith+Nephew offers a broad portfolio of advanced wound care and orthobiologics products, including placental-derived grafts through its Osiris heritage, overlapping with HRT's wound and orthopedic indications.

TypeBroad incumbent
Description

Coloplast's wound care division offers a range of advanced dressings and biologic wound therapies, positioning it as a broad incumbent competitor in the wound care channels HRT serves.

TypeBroad incumbent
Description

ConvaTec provides advanced wound care and skin substitute products (e.g., Avelle, InnovaMatrix) targeting similar hospitals and wound clinics as HRT.

TypeEmerging player
Description

Celularity develops placental-derived and cellular regenerative products for wound care and orthopedics, representing an emerging competitor with overlapping science and indication focus to HRT.

TypeBroad incumbent
Description

Arthrex is a large orthopedic surgical device company with an expanding orthobiologics portfolio that overlaps with HRT's orthopedic and soft tissue repair use cases.

TypeDirect peer
Description

Organogenesis manufactures and sells biologic skin substitutes and wound care products (Apligraf, Dermagraft, PuraPly), competing with HRT in the advanced wound care and regenerative tissue segment.

9Amniox Medical
TypeEmerging player
Description

Amniox Medical markets amniotic membrane-based products (CLARIX, NEOX) for wound healing and surgical applications, an emerging niche player directly overlapping with HRT's placental allograft focus.

TypeBroad incumbent
Description

Integra LifeSciences is an established medical device company with a sizeable regenerative wound care portfolio (Integra Dermal Regeneration Template, amniotic products) that competes with HRT across wound care and surgical soft tissue repair.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Human Regenerative Technologies

Tissue Allograftshumantissue.com

Human Regenerative Technologies, LLC is a U.S. biologics company that processes and distributes human amniotic and placental tissue allografts via its proprietary HydraTek® Process, selling directly to hospitals, surgical centers, and wound care clinics across seven U.S. states and Canada.

What Human Regenerative Technologies does

Human Regenerative Technologies, LLC (HRT®) is a U.S.-based biologics company founded in 2013 and headquartered in El Segundo, California. The company specializes in processing and distributing human amniotic and placental tissue allografts under Section 361 of the Public Health Service Act and 21 CFR Part 1271. Since December 31, 2018 it has operated as a majority-owned subsidiary of Skye Biologics Holdings, LLC, serving as the primary allograft tissue processor for Skye Orthobiologics' placental and amniotic tissue product offering. HRT reports over 250,000 cumulative implants and a management team with more than 50 years of combined experience in the 361 tissue allograft space.

HRT's core technology is the proprietary HydraTek® Process, which the company positions as a differentiated tissue processing method that preserves placental tissue in its natural hydrated state and improves handling and delivery characteristics for clinical use. The product portfolio is organized around wound care applications and extends into surgical soft tissue repair and orthopedic use cases, targeting hospitals, ambulatory surgical centers, and wound care clinics. The company is accredited by the American Association of Tissue Banks (AATB), registered with the FDA, and holds tissue bank licenses in California, New York, Maryland, Oregon, Delaware, and Illinois, with additional licensure in Canada.

HRT's business model is a direct B2B field-sales motion selling per-product and per-procedure allograft units to healthcare institutions, with marketing concentrated at orthopedic, foot and ankle, and wound care conferences (AAOS, ACFAS, SAWC). No headcount, revenue, valuation, or funding data are publicly disclosed; pricing is not published and is negotiated through institutional procurement channels.

Human Regenerative Technologies firmographics

Firmographics
Name
Human Regenerative Technologies
Legal name
Human Regenerative Technologies, LLC
Website
https://humantissue.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Human Regenerative Technologies, LLC is a U.S. biologics company that processes and distributes human amniotic and placental tissue allografts via its proprietary HydraTek® Process, selling directly to hospitals, surgical centers, and wound care clinics across seven U.S. states and Canada.
Ownership category
akta.pro rank

Human Regenerative Technologies industry classification

Industry
Product category
Tissue Allografts
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Amniotic tissue allografts
  • Placental tissue processing
  • Wound care allografts
  • Orthobiologic tissue products
  • Regenerative tissue banking

Where Human Regenerative Technologies is headquartered

Location

Headquarters

HQ city
El Segundo
HQ country
United States
HQ region
North America

Markets served

Human Regenerative Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Amniotic & Placental Allograft Products: HRT generates revenue through the sale of human amniotic and placental tissue allografts, including wound care and soft tissue products derived from placental connective tissues. Revenue is generated on a per-implant/product transaction basis rather than a recurring subscription model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Human Regenerative Technologies product offering

Product offering

Core offering

Human Regenerative Technologies processes and distributes human amniotic and placental tissue allografts for medical applications, primarily wound care and soft tissue repair. Products are manufactured using the proprietary HydraTek® Process, which preserves placental and amniotic tissue in its natural hydrated state to maintain tissue integrity and function. All allografts are regulated under Section 361 of the PHS Act and 21 CFR Part 1271.

Product overview

Human Regenerative Technologies (HRT®) offers a unified portfolio of human amniotic and placental tissue allografts for medical applications. The core offering centers on the proprietary HydraTek® Process technology, which processes and preserves placental tissues in their natural hydrated state. Products include wound care applications derived from amniotic and placental tissues. All products are regulated under 361 of the PHS Act and 21 CFR Part 1271 as human cell, tissue, and cellular and tissue-based products (HCT/Ps).

Differentiator

Problem solved

Functional benefit

Brands

  • HydraTek®: Revolutionary technology and processing method for harvesting and preserving placenta tissue in its natural hydrated state for use as transplant allografts.

Products and services

  • Wound Care Allografts Human amniotic and placental tissue allografts designed for wound care applications, processed using the proprietary HydraTek® technology to preserve tissue in its natural hydrated state. Sold to hospitals, surgical centers, and wound care clinics for patient wound care management.

Quantifiable outcome

  • Over 250,000 implants performed to date

Companies that use Human Regenerative Technologies

Customer profile

Segments2 records

Ideal customer profiles2 records

Human Regenerative Technologies technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Human Regenerative Technologies partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Human Regenerative Technologies competitors and assessment

Company assessment

Direct peers

  • AlloSource: AlloSource is a non-profit tissue bank that processes and distributes allografts including amniotic and placental products, directly comparable as a tissue processor serving wound care and orthopedic surgeons.
  • MiMedx Group: MiMedx develops and markets amniotic membrane tissue allografts (EpiFix, AmnioFix) for wound care and surgical applications, directly overlapping with HRT's placental/amniotic allograft portfolio and customer base.
  • Organogenesis: Organogenesis manufactures and sells biologic skin substitutes and wound care products (Apligraf, Dermagraft, PuraPly), competing with HRT in the advanced wound care and regenerative tissue segment.

Broad incumbents

  • Smith+Nephew: Smith+Nephew offers a broad portfolio of advanced wound care and orthobiologics products, including placental-derived grafts through its Osiris heritage, overlapping with HRT's wound and orthopedic indications.
  • Coloplast: Coloplast's wound care division offers a range of advanced dressings and biologic wound therapies, positioning it as a broad incumbent competitor in the wound care channels HRT serves.
  • ConvaTec: ConvaTec provides advanced wound care and skin substitute products (e.g., Avelle, InnovaMatrix) targeting similar hospitals and wound clinics as HRT.
  • Arthrex: Arthrex is a large orthopedic surgical device company with an expanding orthobiologics portfolio that overlaps with HRT's orthopedic and soft tissue repair use cases.
  • Integra LifeSciences: Integra LifeSciences is an established medical device company with a sizeable regenerative wound care portfolio (Integra Dermal Regeneration Template, amniotic products) that competes with HRT across wound care and surgical soft tissue repair.

Emerging players

  • Celularity: Celularity develops placental-derived and cellular regenerative products for wound care and orthopedics, representing an emerging competitor with overlapping science and indication focus to HRT.
  • Amniox Medical: Amniox Medical markets amniotic membrane-based products (CLARIX, NEOX) for wound healing and surgical applications, an emerging niche player directly overlapping with HRT's placental allograft focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Human Regenerative Technologies social profiles

Digital presence

Human Regenerative Technologies compliance and trust

Trust signal

Compliance3 records

Human Regenerative Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Human Regenerative Technologies leadership team

Management profile

Number of profiles

Human Regenerative Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Human Regenerative Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Human Regenerative Technologies

What does Human Regenerative Technologies do?

Human Regenerative Technologies processes and distributes human amniotic and placental tissue allografts for medical applications, primarily wound care and soft tissue repair. Products are manufactured using the proprietary HydraTek® Process, which preserves placental and amniotic tissue in its natural hydrated state to maintain tissue integrity and function. All allografts are regulated under Section 361 of the PHS Act and 21 CFR Part 1271.

Is Human Regenerative Technologies a public or private company?

Human Regenerative Technologies is a private company. It is classified as corporate owned and is currently operating.

When was Human Regenerative Technologies founded?

Human Regenerative Technologies was founded in 2013. It employs 1 to 10 people.

Where is Human Regenerative Technologies based?

Human Regenerative Technologies is headquartered in El Segundo, United States, in the North America region.

How does Human Regenerative Technologies make money?

One revenue line is on record: amniotic & Placental Allograft Products.

Who are Human Regenerative Technologies's main competitors?

Direct peers on record are AlloSource, MiMedx Group and Organogenesis. Broad incumbents are Smith+Nephew, Coloplast, ConvaTec, Arthrex and Integra LifeSciences. Emerging players are Celularity and Amniox Medical.

Does Human Regenerative Technologies have an API?

No public API is recorded for Human Regenerative Technologies.

What industry is Human Regenerative Technologies in?

Human Regenerative Technologies's product category is Tissue Allografts. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comOphthalmology Amniotic Membrane Market Growth, Trends, & Forecast 2025 | Top key players - FzioMed, Inc., Amniox Medical, Inc., Human Regenerative Technologies, LLC.The ophthalmology amniotic membrane market was valued at USD 403.6 million in 2022 and is projected to grow at a CAGR of 9.80% from 2024 to 2031. Growth is driven by demand for biological bandages in eye surgeries, with key players including FzioMed, Amniox Medical, and Human Regenerative Technologies.PR NewswireHuman Regenerative Technologies, LLC (HRT) Announce WoundEx® Amniotic Membrane Products Receive Coverage From Novitas Solutions, Inc.Novitas Solutions, a Medicare Administrative Contractor, updated its coverage policy to include WoundEx amniotic membrane for lower extremity chronic non-healing wounds. The decision covers 13 states and about 11.3 million Medicare beneficiaries. HRT's CEO expressed excitement about the coverage.PR NewswireHuman Regenerative Technologies, LLC (HRT) Announce WoundEx® Amniotic Membrane Products Receive Coverage From Novitas Solutions, Inc.Human Regenerative Technologies, LLC announced that its WoundEx® amniotic membrane product has received coverage approval from Novitas Solutions, Inc., a Medicare Administrative Contractor. This Local Coverage Determination allows the product to be reimbursable under Medicare for lower extremity chronic non-healing wounds across 13 states, covering approximately 11.3 million beneficiaries. The decision expands the market access for HRT's regenerative biologics within a significant portion of the U.S. healthcare system.